Vaskulitidy – rychlý diagnosticko-terapeutický tahák pro internistu 274 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék. 2026;72(4):268-274 / www.casopisvnitrnilekarstvi.cz VE ZKRATCE LITERATURA 1. Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17:603-606. 2. Alpsoy E. Cutaneous vasculitis; an algorithmic approach to diagnosis. Front Med (Lausanne). 2022;9:1012554. 3. Fraticelli P, Benfaremo D, Gabrielli A. Diagnosis and management of leukocytoclastic vasculitis. Intern Emerg Med. 2021;16:831-841. 4. Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68:1827-1832. 5. Houben E, Bax WA, van Dam B, et al. Diagnosing ANCA-associated vasculitis in ANCA- -positive patients: a retrospective analysis on the role of clinical symptoms and the ANCA titre. Medicine (Baltimore). 2016;95(40):e5096. 6. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61(10):1454-1461. 7. Ponte C, Grayson PC, Robson JC, et al. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis. 2022;81:1647-1653. 8. Dejaco C, Ramiro S, Bond M, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis. 2024;83(6):741-751. 9. Petersdorf RG, Beeson PB. Fever of unexplained origin: report on 100 cases. Medicine (Baltimore). 1961;40:1-30. 10. Vanderschueren S, Del Biondo E, Ruttens D, et al. Inflammation of unknown origin versus fever of unknown origin: two of a kind. Eur J Intern Med. 2009;20(4):415-418. 11. Bleeker-Rovers CP, Vos FJ, de Kleijn EMHA, et al. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore). 2007;86(1):26-38. 12. Béra S, Jamilloux Y, Gerfaud-Valentin M, et al. Inflammation of unknown origin: evaluation and prognosis of 57 cases. J Clin Med. 2021;11(1):32. 13. Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83:30-47. 14. Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622-631. 15. Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317-328. 16. Blockmans D, Penn SK, Setty AR, et al. A phase 3 trial of upadacitinib for giant-cell arteritis. N Engl J Med. 2025;392(20):2013-2024. 17. Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921-1932. 18. Wechsler ME, Nair P, Terrier B, et al. Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2024;390(10):911-921. 19. Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599-609. 20. Hellmich B, Agueda A, Monti S, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19-30. www.kongresCIS.cz XXXIII. KONGRES ČESKÉ INTERNISTICKÉ SPOLEČNOSTI ČLS J. E. PURKYNĚ Kongresové centrum Praha 5. května 1640/65, Praha 4 ve spolupráci s dalšími odbornými společnostmi a s Interní sekcí České asociace sester 6. – 9. 12. 2026 Česká internistická společnost ČLS JEP pořádá SEMINÁŘ K ATESTAČNÍM OTÁZKÁM PRO MLADÉ INTERNISTY 17. září 2026 NOVOTEL Praha Wenceslas Square (Kateřinská 38, Praha 2) Možnost přihlášení na seminář do 10. 9. 2026 na e-mailové adrese: v.strukova@gsymposion.cz
RkJQdWJsaXNoZXIy NDA4Mjc=